Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2003
12/09/2003US6660725 Method and composition for modulating amyloidosis
12/09/2003US6660717 Folliculogenesis
12/09/2003US6660716 Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof
12/09/2003US6660715 Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
12/09/2003US6660714 α-O-linked glycoconjugates, methods of preparation and uses thereof
12/09/2003US6660525 Therapeutic liposome composition and method
12/09/2003US6660521 Use of trans-activation and CIS-activation to increase the persistence of a transgene in an at least E4-deficient adenovirus
12/09/2003US6660520 Nrde
12/09/2003US6660512 Human lysozyme gene, it's encoded polypeptide and the method of preparing them
12/09/2003US6660499 Nucleic acid encoding human DCR5, a protein related to DAN (Differential-screening-selected gene Aberrative in Neuroblastoma)
12/09/2003US6660498 Malaria immunogenic composition
12/09/2003US6660496 Nucleic acid molecules encoding a KOR3 kappa opioid receptor and the methods of producing the encoded receptor
12/09/2003US6660495 Tolerogenic fragments of natural allergens
12/09/2003US6660488 Antibodies for the alpha platelet-derived growth factor receptor
12/09/2003US6660487 Exposing mammal to major histocompatibility complex class I and peptide, prior to, after, or concurrently with treating mammal to kill or inactivate autoimmune cells of mammal for increasing or maintaining number of functional cells
12/09/2003US6660482 Diagnosing sepsis by contacting a bodily fluid with a ligand which binds to an inter-alpha trypsin inhibitor (ITI) polypeptide to form an ITI-ligand complex and detecting the complex.
12/09/2003US6660467 Variant of ciliary neurotrophic factor and DNA encoding the variant
12/09/2003US6660313 1-20 wt% of lactase and cutting agent that is 0-4 parts by weight for each part by weight lactase, 1-98 wt% of microcrystalline cellulose, 0-97 wt% of mannitol, and a lubricant to aid in compression
12/09/2003US6660280 Collagen product containing collagen of marine origin with a low odor and preferably with improved mechanical properties, and its use in the form of cosmetic or pharmaceutical compositions or products
12/09/2003US6660279 Stability for injection solutions
12/09/2003US6660275 Amplification nucleic acids
12/09/2003US6660274 Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
12/09/2003US6660273 Viable chimeric recombinant flavivirus
12/09/2003US6660272 For protection against Porcine Multisystemic Wasting Syndrome also called Post- weaning Multisystemic Wasting Syndrome
12/09/2003US6660270 Immunization of dairy cattle with chimeric GapC protein against Streptococcus infection
12/09/2003US6660269 Canine tropical pancytopenia;
12/09/2003US6660268 Proteasome regulation of NF-KB activity
12/09/2003US6660267 Prevention and treatment of sepsis
12/09/2003US6660266 Ligating agent comprises (i) at least two IgG Fc regions or (ii) a multivalent antibody which binds to Fe gamma I receptor.
12/09/2003US6660258 Administration of Th1 or Th2 specific cytokines via the mucosa lining the oral and/or nasopharyngeal cavities
12/09/2003US6660257 Flt-3 receptor agonist proteins; nucleic acid sequence
12/09/2003US6660256 Thrombocytopenia; the ligand stimulates the incorporation of labeled nucleotides (3H-thymidine) into the DNA of IL-3 dependant Ba/F3 cells transfected with human mpl P, and the amino-terminal sequence is SPAPPACDPRLLNKLLRDDHVLHGR (SEQ ID
12/09/2003US6659995 Autologous myocyte micro granual retrieval and implantation (AMMGRI)
12/09/2003CA2202075C Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
12/09/2003CA2111580C Immunogen composites with noted anticytokin effect, process of preparation, pharmaceutical compositions and kits containing them
12/09/2003CA2078758C 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
12/09/2003CA1341449C Poly-kringle plasminogen activator
12/04/2003WO2003100439A2 Receptor and screening methods
12/04/2003WO2003100438A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003WO2003100436A2 Diagnostics and therapeutics for diseases associated with chemokine receptor 10 (ccr10)
12/04/2003WO2003100435A2 Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
12/04/2003WO2003100434A2 Diagnostic and therapeutic use of the arginine vasopressin receptor 2 (avpr2)
12/04/2003WO2003100433A2 Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
12/04/2003WO2003100432A2 Method for identifying immunoreactive peptides
12/04/2003WO2003100431A1 Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (ccr11)
12/04/2003WO2003100426A1 Diagnostic indicator of sjögren's syndrome
12/04/2003WO2003100419A1 Methods for using the cd163 pathway for modulating an immune response
12/04/2003WO2003100093A2 Method of selecting targets for gene silencing by rna interference
12/04/2003WO2003100087A2 Regulation of novel human asparagine-hydroxylases
12/04/2003WO2003100081A2 Biologically active maleamic acid derivatives with labile amide bonds
12/04/2003WO2003100059A2 Molecular targeting of the igf-1 receptor
12/04/2003WO2003100053A1 Compositions and methods for the treatment of hemophilia a
12/04/2003WO2003100051A1 Palliative treatment for gluten intolerance
12/04/2003WO2003100045A1 Plant thymidine kinases and their use
12/04/2003WO2003100041A1 Cd100 semaphorin in myelination
12/04/2003WO2003100040A1 A method for generating antigen-presenting cells
12/04/2003WO2003100034A2 Dentritic cell nodes
12/04/2003WO2003100031A2 Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
12/04/2003WO2003100027A2 Mutant fibronectin and tumor metastasis
12/04/2003WO2003100025A2 Crisp polypeptides as contraceptives and inhibitors of sperm capacitation
12/04/2003WO2003100024A2 Treatment for diabetes
12/04/2003WO2003100007A2 Eta-1 gene and methods for use
12/04/2003WO2003100005A2 Universal chimera bank
12/04/2003WO2003100001A2 Claudin polypeptides, polynucleotides, and methods of making and use thereof
12/04/2003WO2003099992A2 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
12/04/2003WO2003099991A2 Glp-1 gene delivery for the treatment of type 2 diabetes
12/04/2003WO2003099868A2 Method for obtaining anti-idiotype antibodies
12/04/2003WO2003099864A1 Use of monocarboxylate transporter protein for thyroid hormone transport
12/04/2003WO2003099862A1 Export and modification of (poly)peptides in the lantibiotic way
12/04/2003WO2003099861A1 Use of a pestivirus ns3-like protein for inducing cell apoptosis
12/04/2003WO2003099858A1 Cross-linked glycopeptide-cephalosporin antibiotics
12/04/2003WO2003099857A1 Antagonistic peptides of prostaglandin e2 receptor subtype ep4
12/04/2003WO2003099851A2 Methods and compositions for inhibiting hiv replication
12/04/2003WO2003099850A2 Mutant p53 (δ126-132) protein and uses thereof
12/04/2003WO2003099849A2 Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
12/04/2003WO2003099845A2 Fas peptide mimetics and uses thereof
12/04/2003WO2003099842A2 Compositions and methods of use for a bombesin peptide
12/04/2003WO2003099839A1 Modulators and inhibitors of fibroblast growth factor receptor 5_polypeptides and gene expression thereof.
12/04/2003WO2003099833A2 Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
12/04/2003WO2003099830A2 Cardiolipin compositions, methods of preparation and use
12/04/2003WO2003099787A1 Novel piperidine compound
12/04/2003WO2003099778A2 Inhibitors of proteins from the rho-gef family
12/04/2003WO2003099762A1 Agents and methods for the treatment of disorders associated with oxidative stress
12/04/2003WO2003099362A1 Aerosol drug inhibition of lung metastases
12/04/2003WO2003099340A1 Novel chimeric cd154
12/04/2003WO2003099339A1 Decoy composition for treating and preventing inflammatory disease
12/04/2003WO2003099338A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
12/04/2003WO2003099330A1 Induction and maintenance of tolerance to composite tissue allografts
12/04/2003WO2003099329A1 Chimeric allograft tolerance induction, monitoring and maintenance
12/04/2003WO2003099326A1 Novel uses of parapoxvirus preparations
12/04/2003WO2003099324A1 Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
12/04/2003WO2003099323A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
12/04/2003WO2003099322A2 Il-11 derivatives and therapeutic uses thereof
12/04/2003WO2003099321A1 Methods for preventing, treating or delaying cardiac toxicity using neuregulin
12/04/2003WO2003099320A1 Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
12/04/2003WO2003099319A1 Preventive/remedy for arteriosclerosis
12/04/2003WO2003099318A2 Pancreas-specific proteins
12/04/2003WO2003099317A1 Novel uses of cephaibols
12/04/2003WO2003099316A1 Heterocyclicsulfonamide hepatitis c virus inhibitors
12/04/2003WO2003099315A1 A pharmaceutical composition comprising a retro-iverso isomer peptide
1 ... 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 ... 3163